Close this search box.

AZ, Daiichi see more Enhertu opportunity in breast cancer after HER2-ultralow ASCO data

ARTICLE | Product Development

What’s next for the ADC after it extends PFS in breast cancer patients with barely detectable HER2 

By Lauren Martz, Executive Director, Biopharma Intelligence

June 4, 2024 11:54 PM UTC

Enhertu has surpassed expectations again, with ASCO data proving efficacy in breast cancers when even the lowest detectable amount of HER2 expression is present. There are now data to support Enhertu’s use across the large majority of advanced and metastatic previously treated breast cancers, but AstraZeneca and Daiichi aren’t finished with breast cancer yet. 

The next tests will be whether the HER2-targeted antibody-drug conjugate (ADC) can deliver the same — or even more impressive — results outside the metastatic setting, and whether the safety profile supports use in those applications…